Browsing: Hematologic

In October 2025, the FDA granted priority review to Orca-T as a treatment for patients with acute myeloid leukemia (AML),…

In a conversation with CancerNetwork®, Wendy Stock, MD, discussed what the potential FDA approval of Orca-T would mean for different…

The FDA has extended its review period for a biologics license application (BLA) seeking approval for Orca-T as a treatment…

The Seventh Annual Miami Cancer Institute Immunotherapies Summit for Hematologic Malignancies, hosted by Baptist Health, saw several presentations and sessions…

While polygenic risk scores (PRS) are well-established tools for predicting cancer incidence, their utility in prognosticating survival outcomes through inherited…

Competing interests CV reports research funding from Janssen, Kite Pharma, K36 Therapeutics, Arcellx; consulting or advisory role for Janssen. JAD…

At the Seventh Annual Miami Cancer Institute Immunotherapies Summit for Hematologic Malignancies hosted by Baptist Health, experts across hematologic oncology…

In March 2026, Baptist Health hosted the Seventh Annual Miami Cancer Institute Immunotherapies Summit for Hematologic Malignancies, an event dedicated…

During a visit to Columbia University Irving Cancer Research Center, experts across hematologic oncology shared their perspectives on key trends…

In October 2025, the FDA granted priority review to Orca-T, a novel allogenic T-cell immunotherapy, for the treatment of multiple…